M 5

Drug Profile

M 5

Alternative Names: Lys300His mutant pro-urokinase; M5

Latest Information Update: 15 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Harvard Medical School
  • Developer Harvard Medical School; Tomen
  • Class Plasminogen activator enzymes
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 15 Nov 2012 Discontinued - Preclinical for Thrombosis in Japan (unspecified route)
  • 15 Nov 2012 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
  • 18 Apr 2000 Tomen has licensed M5 from Harvard Medical School for the world
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top